BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
Want to see TSE:BCT full AI Analyst Report?
BCT Stock Chart & Stats
C$10.64
-C$0.02(-3.08%)
At close: 4:00 PM EST
C$10.64
-C$0.02(-3.08%)
Day’s Range― - ―
52-Week RangeC$4.95 - C$76.00
Previous CloseN/A
Volume105.15K
Average Volume (3M)3.11K
Market Cap
C$38.43M
Enterprise Value-C$22.36M
Total Cash (Recent Filing)C$29.65M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding7,250,487
10 Day Avg. Volume3,860
30 Day Avg. Volume3,110
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clean Balance SheetZero reported total debt and a restored positive equity base materially reduce immediate refinancing distress and provide financial flexibility. For a clinical-stage biotech, this strengthens the company's ability to fund development, negotiate partnerships, and manage milestone-driven spend over the next 2–6 months.
Late-stage Clinical ProgressionActive Phase 3 study and additional Phase 2 analyses showcased at a major scientific meeting signify advancement toward potential regulatory milestones or partnering discussions. Sustained progress in late-stage trials can materially de-risk the lead program and attract collaborators or non-dilutive funding over a medium-term horizon.
Next-gen Platform PotentialPreclinical evidence that Bria-OTS+ elicits coordinated innate and adaptive responses suggests a platform capable of addressing multiple solid tumors. A robust platform provides durable upside via pipeline expansion, combination strategies, and licensing or partnership opportunities beyond the lead asset.
Bears Say
No RevenueThe absence of product revenue and persistently negative gross profit reflect a classic pre-commercial biotech profile with no internal cash flow generation. This structural lack of revenue elevates reliance on external capital and makes long-term sustainability contingent on successful trial outcomes or financing events.
High Cash BurnSubstantial negative free cash flow (~-37M TTM) and consistently negative operating cash flow translate R&D and trial costs directly into cash depletion. This persistent burn increases refinancing and dilution risk, constraining runway and strategic optionality absent timely funding or partnership receipts.
Limited Scale Of OperationsA small headcount (16 employees) limits internal capacity to run concurrent late-stage trials, scale manufacturing readiness, or rapidly expand commercialization efforts. This structural constraint increases dependence on external CROs/partners and can slow program timelines or raise execution risk over the medium term.
BriaCell Therapeutics News
BCT FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was C$4.95 and its highest was C$76.00 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is C$38.43M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Jun 17, 2026 which is in 51 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Mar 10, 2026. The company reported -C$3.575 earnings per share for the quarter, missing the consensus estimate of N/A by -C$3.575.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 7,250,487 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -C$3.575 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 15.914%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:BCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BriaCell Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.49%
12-Months-Change
Fundamentals
Return on Equity
-205.87%
Trailing 12-Months
Asset Growth
235.47%
Trailing 12-Months
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―
Options Prices
Currently, No data available
---